Generics Bulletin is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Alexion To Join With AZ Ahead Of US Soliris Biosimilars In 2025

Originator Shifting Patients To Next-Gen Ultomiris

Executive Summary

Amgen will be able to launch its US Soliris biosimilar around two years ahead of patent expiry under a settlement agreement. The brand’s manufacturer, Alexion, discussed the threat as AstraZeneca pounced with a $39bn takeover agreement.

You may also be interested in...



COVID-19 Alters But Doesn’t Change M&A Machine In 2020

Mergers and acquisitions have long been a tool for value creation in the generics and biosimilars space. Even with the entire life sciences sector overwhelmed by the novel coronavirus pandemic, deals big and small continued in 2020.

Alexion Not Scared Of Amgen Biosimilar Threat To Soliris

Alexion Pharmaceuticals is confident of its strategy to switch patients from Soliris to Ultomiris as the threat of biosimilar competition to the former looms. But launching a biosimilar to Soliris alone will be a challenge, the company maintains.

Pegfilgrastim Next As Fresenius Kabi Eyes Five Biosimilars In 2025

Fresenius Kabi has drawn up a roadmap to offering five biosimilar products by 2025, with a biosimilar to Amgen’s Neulasta (pegfilgrastim) set to rival competitors in the US and Europe later this year, ahead of a biosimilar to Roche and Chugai’s Actemra/Ro-Actemra (tocilizumab).

Topics

Related Companies

UsernamePublicRestriction

Register

LL1131980

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel